CUE vs MCD · rev $9.3M vs P/E 23, rev $25.92B
Cue Biopharma (CUE) versus McDonald’s Corporation (MCD) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
McDonald’s Corporation (MCD) is a restaurants company listed on NYSE. It is led by Chris Kempczinski.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported MCD revenue for 2024-12-31 was $25.92B. Net income was $8.22B. Revenue was up 1.7% from 2023-12-31 to 2024-12-31. MCD currently screens at market cap $201.66B and trailing P/E 23.4.
CUE currently screens at market cap $59.5M. MCD currently screens at market cap $201.66B and trailing P/E 23.4.
Not investment advice. Open the CUE and MCD stock pages for the full models.
Not investment advice.